The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~ $6 billion in potential market opportunity PHILADELPHIA, PA / ACCESS Newswire / September 18, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and disruptive therapeutics assets, is pleased to announce that it has entered into a purchase agreement (the "Purchase Agreement") with YA II PL, Ltd. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP, pursuant to which the Company has issued and Yorkville has purchased a non-dilutive debenture (the "Debenture") in $8.0 million principal amount. The Debenture, which is guaranteed by each of the Company's subsidiaries, bears interest at an annual rate of 8%, matures twelve months from the date of issuance and is repayable in monthly installments together with accrued and unpaid interest, with all remaining principal and interest due and payable on the maturity date. Certain payments on the Debenture may be withheld by Yorkville from the proceeds of the previously announced standby equity purchase agreement (the "SEPA") between the Company and Yorkville.